Equity · Healthcare
CRSP
NASDAQCRISPR Therapeutics (CRSP)
The line runs 57 USD on 24 August through 39.16 USD on 20 November, on a scale from 30 to 70. Days the market did not trade hold the previous close, flat.
- Market cap
- 3.8B USD
- Revenue, year to Dec 2025
- 3.5M USD
- EPS, diluted, year to Dec 2025
- −6.47 USD
- 52-week range
- 38.87 USD – 61.91 USD
- Avg volume
- 83.2K
- Mentions, 30 days
- 13
- Net sentiment
- +0.05
as of Nov 20, 2026
Have CRISPR Therapeutics (CRSP) insiders bought or sold shares recently?
In the 90 days to 23 Nov 2026, CRISPR Therapeutics insiders reported 7 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 18 Dec 2025, show no open-market purchase.
Form 4, 90 days to 23 Nov 2026, newest reported trade 19 Oct 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 19 Oct 2026 | Kulkarni SamarthChief Executive Officer | Sell | 47,837 | 2.4M USD |
| 14 Oct 2026 | George SimeonDirector | Sell | 14,514 | 720K USD |
| 14 Oct 2026 | KASINGER JAMES R.General Counsel and Secretary | Sell | 1,040 | 51K USD |
| 14 Oct 2026 | Kulkarni SamarthChief Executive Officer | Sell | 4,098 | 202K USD |
| 06 Oct 2026 | KASINGER JAMES R.General Counsel and Secretary | Sell | 1,990 | 119K USD |
| 22 Sep 2026 | KASINGER JAMES R.General Counsel and Secretary | Sell | 10,400 | 626K USD |
| 17 Sep 2026 | Behbahani AliDirector | Sell | 13,679 | 781K USD |
| Sold | 7 open-market sales | 93,558 | $4.88M |
8 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 17 Nov 2026 | Kulkarni SamarthChief Executive Officer | Gift | 100,000 | |
| 16 Oct 2026 | Kulkarni SamarthChief Executive Officer | Option exercise | 100,000 | |
| 14 Oct 2026 | George SimeonDirector | Option exercise | 30,000 | 420K USD |
| 13 Oct 2026 | KASINGER JAMES R.General Counsel and Secretary | Option exercise | 2,113 | |
| 13 Oct 2026 | Kulkarni SamarthChief Executive Officer | Option exercise | 8,333 | |
| 06 Oct 2026 | KASINGER JAMES R.General Counsel and Secretary | Option exercise | 1,990 | 27K USD |
| 22 Sep 2026 | KASINGER JAMES R.General Counsel and Secretary | Option exercise | 10,400 | 142K USD |
| 17 Sep 2026 | Behbahani AliDirector | Option exercise | 30,000 | 420K USD |
Which funds hold CRISPR Therapeutics (CRSP)?
9 of the 45 institutional funds we track reported a CRISPR Therapeutics position for the quarter ended 30 Sep 2026 — a combined 729.1M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| ARK Investment Management | Held (±25%) | 10,056,844 | 556.3M USD | +6.3% |
| Two Sigma Investments | Held (±25%) | 2,016,038 | 111.5M USD | +1.4% |
| D. E. Shaw & Co. | Trimmed | 518,906 | 28.7M USD | −41.9% |
| Man Group | Added | 329,602 | 18.2M USD | +350.3% |
| Millennium Management | Trimmed | 91,630 | 5.1M USD | −76.0% |
| Fisher Asset Management | Held (±25%) | 67,302 | 3.7M USD | −13.7% |
| Tudor Investment Corp | Held (±25%) | 52,520 | 2.9M USD | +23.5% |
| AQR Capital Management | Added | 41,907 | 2.3M USD | +46.5% |
| Citadel Advisors | Trimmed | 4,680 | 259K USD | −99.0% |
Have members of Congress traded CRISPR Therapeutics (CRSP)?
The most recent congressional trade disclosed in CRISPR Therapeutics is a purchase by Thomas R. Suozzi (house, NY), dated 03 Jun 2021.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 03 Jun 2021 | Thomas R. Suozzihouse · Democrat–NY | Purchase | 50K USD–100K USD | 112 days |
What has been filed or recorded for CRISPR Therapeutics (CRSP)?
The filings we hold for CRISPR Therapeutics, newest first: 9 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 30 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 30 Oct 2026 | Fails to deliver | Shares failed to deliver | 1,718 shares | 93K USD notional · 0.002% of shares out |
| 28 Oct 2026 | Fails to deliver | Shares failed to deliver | 293 shares | 15K USD notional · <0.001% of shares out |
| 27 Oct 2026 | Fails to deliver | Shares failed to deliver | 64 shares | 3K USD notional · <0.001% of shares out |
| 21 Oct 2026 | Fails to deliver | Shares failed to deliver | 68 shares | 3K USD notional · <0.001% of shares out |
| 20 Oct 2026 | Fails to deliver | Shares failed to deliver | 4,084 shares | 204K USD notional · 0.004% of shares out |
| 19 Oct 2026 | Fails to deliver | Shares failed to deliver | 30,328 shares | 1.5M USD notional · 0.031% of shares out |
| 16 Oct 2026 | Fails to deliver | Shares failed to deliver | 4,898 shares | 252K USD notional · 0.005% of shares out |
| 15 Oct 2026 | Fails to deliver | Shares failed to deliver | 37,286 shares | 1.9M USD notional · 0.038% of shares out |
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 9,578 shares | 483K USD notional · 0.010% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −1.15 USD | |
| 30 Sep 2026 | Financials | Total assets | 2.6B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 1.6B USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.94 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −1.28 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −6.47 USD | |
| 31 Dec 2025 | Financials | Revenue | 3.5M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −581.6M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −6.47 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −1.17 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −2.40 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −1.58 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −4.34 USD |
What is Reddit saying about CRISPR Therapeutics (CRSP)?
Reddit mentioned CRSP 13 times in the 30 days to 22 November 2026, across 4 of the communities we track. All of them were scored for sentiment: 46% read bullish, 23% bearish and 31% neither. Reddit data updated 22 November 2026.
30-day window, Method
How do Reddit mentions of CRISPR Therapeutics (CRSP) compare with its price?
Share ↗
Which subreddits are talking about CRISPR Therapeutics (CRSP)?
30 days
| Community | Share | Mentions | Net sentiment |
|---|---|---|---|
| r/wallstreetbets | 77% | 10 | +0.05 |
| r/etfs | 8% | 1 | +0.01 |
| r/stocks | 8% | 1 | +0.03 |
| r/investing | 8% | 1 | +0.09 |
Which names move with CRISPR Therapeutics (CRSP) on Reddit?
JNJ moved most closely with CRISPR Therapeutics (CRSP): when the crowd talked about one, it talked about the other (+0.63 over 31 days). Co-discussion, not price.
International Monetary Fund | Medicare | |||||
|---|---|---|---|---|---|---|
CRSP | +0.63 | +0.63 | +0.60 | +0.60 | +0.60 | +0.59 |
View the matrix as a tableHide the table
| Pair | Match | Days measured |
|---|---|---|
| CRSP and JNJ | +0.63 | 31 days |
| CRSP and CME | +0.63 | 31 days |
| CRSP and International Monetary Fund | +0.60 | 31 days |
| CRSP and Medicare | +0.60 | 31 days |
| CRSP and RPG | +0.60 | 31 days |
| CRSP and LRCX | +0.59 | 31 days |
What do people ask about CRISPR Therapeutics (CRSP)?
What did CRISPR Therapeutics shares close at?39.16
CRISPR Therapeutics closed at 39.16 USD on 20 Nov 2026, up 0.75% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is CRISPR Therapeutics’ market cap?3.8B
CRISPR Therapeutics is worth 3.8B USD by market value as of 20 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is CRISPR Therapeutics’ revenue?3.5M
CRISPR Therapeutics reported revenue of 3.5M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have CRISPR Therapeutics insiders bought or sold shares recently?7 sales
In the 90 days to 23 Nov 2026, CRISPR Therapeutics insiders reported 7 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 18 Dec 2025, show no open-market purchase. A further 8 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own CRISPR Therapeutics?9 of 45
9 of the 45 funds we track reported a CRISPR Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were ARK Investment Management, Two Sigma Investments and D. E. Shaw & Co. See Funds
Have members of Congress traded CRISPR Therapeutics?1 trade
Yes. 1 trade in CRISPR Therapeutics appears in the congressional disclosures we hold: a purchase by Thomas R. Suozzi (House, NY) dated 3 Jun 2021, filed 23 Sep 2021. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did CRISPR Therapeutics last report earnings?−1.15
CRISPR Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −1.15 USD; no next date is announced in SEC filings yet. See Filings
What is Reddit saying about CRISPR Therapeutics?4 mentions
CRISPR Therapeutics was mentioned 4 times in the last 7 days across the finance subreddits we track, and 13 times over the trailing 30 days. Of the 13 mentions scored for sentiment, 46% read bullish and 23% bearish. That is a social signal, not investment advice. See Reddit

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- RedditReddit ingest across the tracked finance subreddits
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- Wikimedia CommonsPortraits via Wikimedia Commons. Thomas R. Suozzi: Österreichisches Außenministerium (BMEIA/ Michael Gruber), CC BY 4.0.
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words